Session Type: ACR Concurrent Abstract Session
Session Time: 4:30PM-6:00PM
Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) based on clinical trials in patients ≥2 years of age. This phase 1 study (NP25737), the first of a biologic in patients with sJIA <2 years of age, evaluated the pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of TCZ.
Methods: Patients with uncontrolled sJIA and symptoms for ≥1 month prescreening whose treatment with corticosteroids and NSAIDs failed and who had no history of allergy to TCZ or other biologics received open-label TCZ 12 mg/kg intravenously every 2 weeks (dose calculated each visit based on body weight). Patients were treated up to Week 12 and could continue until they reached 2 years of age or were treated for 1 year from baseline. End points included PK (primary), safety (secondary), PD, and efficacy (exploratory) at Week 12. Comparison was made with data from a previous trial in sJIA patients ≥2 years of age (WA18221) that formed the basis for approval of TCZ in sJIA.
Results: Eleven patients were enrolled; mean (SD) age was 1.3 (0.33) years, and weight was 9.97 (1.38) kg. Serum TCZ concentrations, estimated using population PK analysis, peaked immediately after infusion; median (range) maximum concentration was 282 (195-347) mcg/mL (steady state reached by Week 12), and median (range) trough concentration was 34.3 (19.2-59.7) mcg/mL. Peak and trough exposures were within the exposure range in older children (244 [109-382] to 54.3 [10.9-117] mcg/mL) (Figure). Observed mean±SD soluble IL-6 receptor levels increased from 47.65±16.40 ng/mL at baseline to 1461.14±852.71 ng/mL at Day 85. CRP and ESR levels, which were elevated at baseline, decreased to 3.35±3.77 mg/L and 3.50±0.84 mm/h, respectively. Mean±SD Juvenile Arthritis Disease Activity Score-71 improved from 22.27±10.09 at baseline to 4.90±6.11 at Day 85. By Week 12, 10 patients had 32 adverse events (AEs); 4 withdrew due to AEs. Infections or infestations were the most frequently reported AEs (10 events, 9 patients). Five serious AEs (SAEs) occurred in 3 patients; all had SAEs of hypersensitivity that led to treatment withdrawal, and 1 of these 3 patients then experienced SAEs of foot and mouth disease and sJIA flare after study withdrawal. No deaths occurred during the study.
Conclusion: TCZ exposures achieved in this study fell within the exposure range of the previous trial in sJIA patients ≥2 years of age. This study provides evidence that TCZ is effective in sJIA patients <2 years of age and achieves PK and efficacy similar to those demonstrated previously in older patients. The safety profile was similar to that observed in patients ≥2 years of age in types of AEs observed, with the exception of a higher incidence of serious hypersensitivity events.
To cite this abstract in AMA style:Mallalieu NL, Hsu J, Wang K, Wimalasundera S, Douglass W, Wells C, Calvo I, Cuttica R, Huppertz HI, Joos R, Kimura Y, Milojevic D, Rosenkranz M, Schikler K, Constantin T, Wouters C. Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age with Systemic Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-a-dosing-regimen-for-tocilizumab-in-patients-younger-than-two-years-of-age-with-systemic-juvenile-idiopathic-arthritis-2/. Accessed January 25, 2020.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-a-dosing-regimen-for-tocilizumab-in-patients-younger-than-two-years-of-age-with-systemic-juvenile-idiopathic-arthritis-2/